Vaxart (NASDAQ:VXRT) announces pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”
The study was designed to assess the relative immunogenicity of four candidate vaccines expressing multiple combinations of the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus in a standard mouse model. Key findings are as follows:
IgA response in the lungs of animals was induced, which is indicative of a mucosal immune response. Particularly, neutralizing antibodies in the lungs were observed at a very high percentage of the total antibody response.
Immunization with our vaccine candidate expressing full length S and N proteins induced IgG responses in a dose-dependent manner.
Antigen-specific CD4+ and CD8+ T cells were induced at both low and high doses.
Vaccine administration induced only low levels of IL-4 production, suggesting little risk of vaccine- dependent disease enhancement.
Vaxart stock has sunk in recent weeks, from $17 to ~$5, but this is still a huge premium to early 2020 low of $0.35. VXRT YTD growth is around 1,300%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.